Purpose: This follow-up of a randomized study was conducted to assess the long-term effects of external beam radiation therapy (EBRT) in the adjuvant treatment of early-stage endometrial cancer.
Patients And Methods: Between 1968 and 1974, 568 patients with stage I endometrial cancer were included. After primary surgery, patients were randomly assigned to either vaginal radium brachytherapy followed by EBRT (n = 288) or brachytherapy alone (n = 280). Overall survival was analyzed by using the Kaplan-Meier method. A Cox proportional hazards model was used to estimate hazard ratios (HRs) with 95% CIs. We also conducted analyses stratified by age groups.
Results: After median 20.5 years (range, 0 to 43.4 years) of follow-up, no statistically significant difference was revealed in overall survival (P = .186) between treatment groups. However, women younger than age 60 years had significantly higher mortality rates after EBRT (HR, 1.36; 95% CI, 1.06 to 1.76) than the control group. The risk of secondary cancer increased after EBRT, especially in women younger than age 60 years (HR, 2.02; 95% CI, 1.30 to 3.15).
Conclusion: We observed no survival benefit of external pelvic radiation in early-stage endometrial carcinoma. In women younger than age 60 years, pelvic radiation decreased survival and increased the risk of secondary cancer. Adjuvant EBRT should be used with caution, especially in women with a long life expectancy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2013.48.8023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison between the SGRT and the conventional setup method for patients undergoing VMAT for pelvic malignancies.
Appl Radiat Isot
January 2025
Department of Medical Physics, Medical School, University of Crete, Heraklion, Greece. Electronic address:
Purpose: Surface Guided Radiation Treatment (SGRT) is a new method of positioning and monitoring patients on the linear accelerator's couch, using visual light cameras to monitor the skin's surface. The purpose of this study was to compare the SGRT with the conventional method, based on lasers and tattoos, in terms of accuracy and time expenditure, on patients with pelvic malignancies.
Materials And Methods: A group of 34 patients were enrolled in this study, 24 males who underwent radiotherapy prostate treatment and 10 females who underwent gynecological radiation therapy.
CAR/CSAR Practice Statement on Pelvic MRI for Endometriosis.
Can Assoc Radiol J
January 2025
Department of Radiology, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
The Canadian Association of Radiologists (CAR) Endometriosis Working Group was tasked with providing guidance and benchmarks to ensure the quality of technique and interpretation for advanced imaging modalities associated with diagnosing endometriosis. Advanced pelvic ultrasound is essential in diagnosing and mapping pelvic endometriosis, but pelvic MRI serves as an excellent imaging tool in instances where access to advanced ultrasound is limited, or an alternative imaging modality is required. Despite the known utility of MRI for endometriosis, there is no consensus on imaging protocol and patient preparation in Canada.
View Article and Find Full Text PDFInvestigating the Local Effectiveness of Carbon Ion Radiotherapy for Unresectable Female Genital Tract Melanomas: A Preliminary Real-World Study.
Cancers (Basel)
December 2024
Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, 27100 Pavia, Italy.
: Primary gynecological melanomas are rare malignancies with lower survival rates compared to cutaneous melanomas. Both preclinical and clinical data support the evidence that mucosal melanomas are photon-radioresistant but responsive to carbon ion radiotherapy (CIRT). The aim of this study is to assess, in a real-world cohort, the effectiveness and tolerability of radical CIRT in patients with inoperable gynecological mucosal melanoma.
View Article and Find Full Text PDFA Technique for the Internalization of Nephroureteral Stents in Patients With Ileal Conduits.
Cureus
December 2024
Department of Interventional Radiology, St James's Hospital, Dublin, IRL.
We present a method of internalization of nephroureteral stents to internalized ureteral stents in a patient with an ileac conduit urostomy with radiation-induced ureteral strictures, and recurrent urinary tract infections (UTIs). This technique is applicable to patients requiring internalization of nephroureteral stents in the setting of an ileal conduit, emphasizing patient consent, preparation, position, imaging guidance, and antibiotic prophylaxis. The successful application of this technique offers a practical solution for managing recurrent UTIs in patients with similar medical histories, providing both clinical and procedural insights.
View Article and Find Full Text PDFLow- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
J Nucl Med
January 2025
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Article Synopsis
- The study compares the definitions of high-volume disease (HVD) and low-volume disease (LVD) in metastatic hormone-sensitive prostate cancer (mHSPC) patients using both conventional imaging (CI) and prostate-specific membrane antigen (PSMA) PET imaging, highlighting the need for more accurate definitions for treatment decisions.
- Researchers analyzed data from 67 mHSPC patients across five international sites who had both PSMA PET and CI scans within a specific timeframe, assessing how many were classified as HVD or LVD based on each imaging method.
- Results showed a significant discrepancy in classification: 25.4% of patients were identified as HVD using CI, while 40.3% were identified as HVD using
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!